Authors: | Royston, L.; Papanicolaou, G. A.; Neofytos, D. |
Review Title: | Refractory/resistant cytomegalovirus infection in transplant recipients: An update |
Abstract: | Despite the significant progress made, CMV infection is one of the most frequent infectious complications in transplant recipients. CMV infections that become refractory or resistant (R/R) to the available antiviral drugs constitute a clinical challenge and are associated with increased morbidity and mortality. Novel anti-CMV therapies have been recently developed and introduced in clinical practice, which may improve the treatment of these infections. In this review, we summarize the treatment options for R/R CMV infections in adult hematopoietic cell transplant and solid organ transplant recipients, with a special focus on newly available antiviral agents with anti-CMV activity, including maribavir and letermovir. © 2024 by the authors. |
Keywords: | adult; review; hematopoietic stem cell transplantation; drug effect; drug resistance; physiology; virology; antivirus agent; drug administration; drug therapy; quinazolines; cytomegalovirus infection; quinazoline derivative; cytomegalovirus; graft recipient; intravenous drug administration; pharmacology; antiviral resistance; drug resistance, viral; oral drug administration; antiviral agents; infectious complication; acetic acid derivative; drug interaction; etiology; adverse event; complication; organ transplantation; benzimidavir; transplant recipients; cytomegalovirus infections; acetates; humans; human; dichlororibofuranosylbenzimidazole; letermovir; 5,6 dichlorobenzimidazole riboside; cytomegalovirus (cmv); maribavir; refractory infection; resistant infection |
Journal Title: | Viruses |
Volume: | 16 |
Issue: | 7 |
ISSN: | 1999-4915 |
Publisher: | MDPI |
Date Published: | 2024-07-01 |
Start Page: | 1085 |
Language: | English |
DOI: | 10.3390/v16071085 |
PUBMED: | 39066247 |
PROVIDER: | scopus |
PMCID: | PMC11281367 |
DOI/URL: | |
Notes: | Source: Scopus |